Breaking News Instant updates and real-time market news.

JUNO

Acquired by CELG

$67.81

-3.56 (-4.99%)

, CELG

Celgene

$102.65

0.93 (0.91%)

11:54
01/22/18
01/22
11:54
01/22/18
11:54

Juno Therapeutics downgraded to Hold from Buy at Needham

Needham analyst Chad Messer downgraded Juno Therapeutics (JUNO) to Hold from Buy after the company agreed to be acquired by Celgene (CELG) for $87 per share. He does not expect additional bidders and thinks the deal will close under the current terms, Messer tells investors.

JUNO

Acquired by CELG

$67.81

-3.56 (-4.99%)

CELG

Celgene

$102.65

0.93 (0.91%)

  • 22

    Jan

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

JUNO Acquired by CELG
$67.81

-3.56 (-4.99%)

01/22/18
JEFF
01/22/18
NO CHANGE
Target $125
JEFF
Buy
Celgene, Juno deal 'smart' if more than JCAR017 plays out, says Jefferies
Following the announced acquisition of Juno Therapeutics (JUNO) by Celgene (CELG), Jefferies analyst Michael Yee notes that in the short term, the Street will debate whether pivotal Juno data coming will look better than Kite's (GILD) Yescarta and whether JCAR17 is truly differentiated. Longer-term, the analyst believes this is a deal hinged on Celgene's confidence in going "all in" on cell therapy over the next 5-10 years. Like Gilead/Kite, this will be a "smart deal" if more than just JCAR17 plays out, he contends, adding that he thinks it will over next few years. Yee reiterates a Buy rating and $125 price target on Celgene's shares.
01/22/18
GUGG
01/22/18
DOWNGRADE
GUGG
Neutral
Juno Therapeutics downgraded to Neutral from Buy at Guggenheim
Juno Therapeutics (JUNO) is being acquired by Celgene (CELG) for $87 per share in cash.
01/22/18
PIPR
01/22/18
NO CHANGE
PIPR
Neutral
Celgene set high bar for Juno deal, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond believes the acquisition of Juno Therapeutics (JUNO) makes good strategic sense for Celgene (CELG). The analyst, however, believes Celgene set a "relatively high" bar by guiding to peak revenue of $3B for lead candidate JCAR017 in non-Hodgkin lymphoma. Raymond keeps a Neutral rating on Celgene shares.
01/18/18
01/18/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Symantec (SYMC) downgraded to Underperform from Hold at Jefferies with analyst John DiFucci saying the company's current guidance is not achievable and the stock will rerate lower upon investor realization. 2. Juno Therapeutics (JUNO) downgraded to Neutral from Buy at Citi with analyst Robyn Karnauskas saying Juno could be worth $110 per share in a takeover. 3. Comcast (CMCSA) downgraded to Neutral from Buy at Nomura Instinet with analyst Jeffrey Kvaal saying the company faces "heightened challenges" with over-the-top services driving declines in linear video and broadband growth likely to slow. 4. First Solar (FSLR) downgraded to Neutral from Buy at Guggenheim with analyst Sophie Karp citing valuation and limited near-term catalysts. 5. Chevron (CVX) downgraded to Hold from Buy at HSBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CELG Celgene
$102.65

0.93 (0.91%)

01/18/18
SBSH
01/18/18
DOWNGRADE
Target $81
SBSH
Neutral
Citi downgrades Juno to Neutral, says potential takeover priced in
Citi analyst Robyn Karnauskas last night downgraded Juno Therapeutics (JUNO) to Neutral from Buy while raising her price target for the shares to $81 from $59. Juno closed yesterday up 52%, or $23.65, to $69.25 after the Wall Street Journal reported that Celgene (CELG) is in talks to acquire the company. When the story broke, Karnauskas said in a research note that Juno could be worth $110 per share in a takeover. She believes, however, that for Celgene, a deal makes sense in the $80-$85 per share range. The analyst expects Juno to trade with an M&A premium at $81 per share. With the recent 49% jump in shares, and the stock now trading within 17% of our takeover price, Karnauskas tells investors in a research note.
01/17/18
CANT
01/17/18
NO CHANGE
CANT
Celgene acquisition of Juno 'doable' but questionable, says Cantor
Cantor Fitzgerald analyst Mara Goldstein maintained a Neutral rating and $112 price target on Celgene Corporation (CELG), noting that Celgene is reportedly in talks to buy the 90% of Juno Therapeutics (JUNO) that it does not already own. While Goldstein sees this potential acquisition as "doable," she questions whether it is "likely to provide a material enough offset near term to fully allay concerns regarding REVLIMID's patent expiration." In afternoon trading, Celgene shares have declined over 2.5%, while Juno shares have shot up over 49%.

TODAY'S FREE FLY STORIES

01:45
08/14/18
08/14
01:45
08/14/18
01:45
General news
Asian Market Wrap: »

Asian Market Wrap:…

BCE

BCE

$40.57

0.045 (0.11%)

21:57
08/13/18
08/13
21:57
08/13/18
21:57
Upgrade
BCE rating change at Edward Jones »

BCE upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SWCH

Switch

$13.96

-0.11 (-0.78%)

21:55
08/13/18
08/13
21:55
08/13/18
21:55
Downgrade
Switch rating change at Raymond James »

Switch downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

FDC

First Data

$23.90

-0.78 (-3.16%)

21:55
08/13/18
08/13
21:55
08/13/18
21:55
Syndicate
First Data 64M share Secondary priced at $23.75 »

Citi acted as lead book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 14

    Aug

ARDS

Aridis Pharmaceuticals

$0.00

(0.00%)

21:54
08/13/18
08/13
21:54
08/13/18
21:54
Syndicate
Aridis Pharmaceuticals 2M share IPO priced at $13.00 »

The deal priced at the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

JPM

JPMorgan

$113.88

-1.8 (-1.56%)

20:52
08/13/18
08/13
20:52
08/13/18
20:52
Periodicals
JPMorgan to stop offering investment accounts to foreign clients, Bloomberg says »

JPMorgan will discontinue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Oct

BIIB

Biogen

$340.67

-2.54 (-0.74%)

20:47
08/13/18
08/13
20:47
08/13/18
20:47
Periodicals
UK's NICE: Biogen's Spinraza too expensive for health service, Reuters reports »

U.K.'s National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

HD

Home Depot

$194.11

-2.19 (-1.12%)

, TPR

Tapestry

$47.42

-0.52 (-1.08%)

20:25
08/13/18
08/13
20:25
08/13/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

HD

Home Depot

$194.11

-2.19 (-1.12%)

TPR

Tapestry

$47.42

-0.52 (-1.08%)

AAP

Advance Auto Parts

$144.79

-1.52 (-1.04%)

EAT

Brinker

$43.81

-0.37 (-0.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 14

    Aug

  • 12

    Sep

HIL

Hill International

$5.65

(0.00%)

19:45
08/13/18
08/13
19:45
08/13/18
19:45
Hot Stocks
Hill International provides update on NYSE notice of delisting »

Hill Internationa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NVDA

Nvidia

$256.08

1.38 (0.54%)

19:36
08/13/18
08/13
19:36
08/13/18
19:36
Hot Stocks
Nvidia launches Turing GPU architecture in computer graphics »

NVIDIA today reinvented…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Aug

ESRX

Express Scripts

$84.04

0.39 (0.47%)

, CI

Cigna

$181.78

-1.59 (-0.87%)

19:33
08/13/18
08/13
19:33
08/13/18
19:33
Hot Stocks
Carl Icahn says will no longer vote against Cigna/Express Scripts deal »

Today Carl Icahn released…

ESRX

Express Scripts

$84.04

0.39 (0.47%)

CI

Cigna

$181.78

-1.59 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 24

    Aug

  • 24

    Aug

MEOH

Methanex

$71.55

-0.45 (-0.63%)

19:17
08/13/18
08/13
19:17
08/13/18
19:17
Hot Stocks
Methanex signs natural gas supply agreement for Chile operations »

Methanex announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PERY

Perry Ellis

$29.10

-0.03 (-0.10%)

19:16
08/13/18
08/13
19:16
08/13/18
19:16
Periodicals
Randa nearing decision on competing Perry Ellis bid, WWD reports »

Randa is in talks with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCBK

TriCo Bancshares

$39.20

-0.14 (-0.36%)

19:01
08/13/18
08/13
19:01
08/13/18
19:01
Hot Stocks
TriCo Bancshares names Peter Wiese as CFO, effective August 14 »

TriCo Bancshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 07

    Nov

ARQL

ArQule

$5.67

0.21 (3.85%)

, YEXT

Yext

$22.57

-0.18 (-0.79%)

19:01
08/13/18
08/13
19:01
08/13/18
19:01
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: ArQule (ARQL) up…

ARQL

ArQule

$5.67

0.21 (3.85%)

YEXT

Yext

$22.57

-0.18 (-0.79%)

CWT

California Water Service

$40.05

-0.4 (-0.99%)

SJW

SJW Corp.

$62.49

0.74 (1.20%)

VERI

Veritone

$15.81

1.05 (7.11%)

SWCH

Switch

$13.96

-0.11 (-0.78%)

VIPS

Vipshop

$8.98

-0.15 (-1.64%)

SAIL

SailPoint

$28.39

-0.43 (-1.49%)

RH

RH

$151.63

7.175 (4.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 13

    Aug

  • 14

    Aug

  • 04

    Sep

  • 04

    Sep

  • 10

    Sep

  • 16

    Aug

ROSE

Rosehill Resources

$8.36

-0.09 (-1.07%)

19:01
08/13/18
08/13
19:01
08/13/18
19:01
Earnings
Rosehill Resources reports Q2 net income $8.7M vs. loss ($1.4M) last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Aug

CMC

Commercial Metals

$21.80

0.11 (0.51%)

18:49
08/13/18
08/13
18:49
08/13/18
18:49
Upgrade
Commercial Metals rating change at Goldman Sachs »

Commercial Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Sep

KALU

Kaiser Aluminum

$109.76

-1.35 (-1.22%)

18:44
08/13/18
08/13
18:44
08/13/18
18:44
Downgrade
Kaiser Aluminum rating change at Goldman Sachs »

Kaiser Aluminum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESTA

Establishment Labs

$27.10

0.66 (2.50%)

18:09
08/13/18
08/13
18:09
08/13/18
18:09
Initiation
Establishment Labs initiated at BTIG »

Establishment Labs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Aug

BRK.A

Berkshire Hathaway

$310,200.00

-1950 (-0.62%)

, BRK.B

Berkshire Hathaway

$205.17

-1.365 (-0.66%)

18:08
08/13/18
08/13
18:08
08/13/18
18:08
Hot Stocks
Berkshire Hathaway comments on quarterly reporting on Form 13F »

"Tomorrow afternoon,…

BRK.A

Berkshire Hathaway

$310,200.00

-1950 (-0.62%)

BRK.B

Berkshire Hathaway

$205.17

-1.365 (-0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PRO

Pros Holdings

$39.80

-0.2 (-0.50%)

18:06
08/13/18
08/13
18:06
08/13/18
18:06
Syndicate
PROS Holdings 450K share Block Trade; price range $7.60-$7.80 »

Barclays is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 14

    Aug

  • 20

    Aug

  • 21

    Aug

  • 16

    Aug

YY

YY

$87.72

-1.09 (-1.23%)

18:06
08/13/18
08/13
18:06
08/13/18
18:06
Earnings
Breaking Earnings news story on YY »

YY sees Q3 revenue growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 10

    Sep

ICUI

ICU Medical

$293.00

0.85 (0.29%)

18:05
08/13/18
08/13
18:05
08/13/18
18:05
Syndicate
ICU Medical 700K share Block Trade; price range $287-$290 »

Barclays is acting as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

YY

YY

$87.72

-1.09 (-1.23%)

18:05
08/13/18
08/13
18:05
08/13/18
18:05
Earnings
YY reports Q2 adjusted EPS $2.03, consensus $1.77 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Aug

  • 10

    Sep

LAC

Lithium Americas

$3.56

-0.17 (-4.56%)

, SQM

SQM

$45.68

-1.16 (-2.48%)

18:03
08/13/18
08/13
18:03
08/13/18
18:03
Hot Stocks
Lithium Americas to partner with Ganfeng Lithium in Cauchari-Olaroz »

Lithium Americas (LAC) is…

LAC

Lithium Americas

$3.56

-0.17 (-4.56%)

SQM

SQM

$45.68

-1.16 (-2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.